For the Inventor, By the Inventor

Enter assignee name

Amsterdam Zuidoost, Netherlands

Aimm Therapeutics B.v.

USPTO Granted Patents = 22

CIPO Patents = 12

EPO Patents = 9

Forward Citations = 43

Loading Chart...

Loading Chart...

56 inventors (with patents filed for the assignee):

Tim Beaumont (16 out of 29 patents)

Hergen Spits (13 out of 25 patents)

Mark Jeroen Kwakkenbos (12 out of 17 patents)

4. Eric J Brown (6 out of 12 patents)

5. Sanjeev Mariathasan (6 out of 16 patents)

6. John Hiroshi Morisaki (6 out of 11 patents)

7. Wouter L W Hazenbos (6 out of 7 patents)

8. Kimberly Kajihara (6 out of 7 patents)

9. Yi Xia (6 out of 7 patents)

10. Adrianus Quirinus Bakker (6 out of 16 patents)

11. Koen Wagner (4 out of 5 patents)

12. Remko Schotte (2 out of 3 patents)

13. Etsuko Yasuda (2 out of 9 patents)

14. Ferenc A Scheeren (2 out of 5 patents)

15. Sean A Diehl (2 out of 3 patents)

22 patents: Sort by Forward Citations

1. 11136407 - Therapeutic anti-CD9 antibody (2021-10-05),

2. 10774308 - Means and methods for influencing the stability of cells (2020-09-15),

3. 10690658 - Means and methods for determining T cell recognition (2020-06-23),

4. 10611829 - Means and methods for producing stable antibodies (2020-04-07),

5. 10556963 - Means and methods for counteracting myeloproliferative or lymphoproliferative disorders (2020-02-11),

6. 10344076 - Means and methods for producing high affinity antibodies (2019-07-09),

7. 10077427 - Means and methods for influencing the stability of cells (2018-09-18),

8. 10017562 - RSV G protein specific antibodies (2018-07-10),

9. 9969795 - Means and methods for producing high affinity antibodies (2018-05-15),

10. 9927428 - Gram-positive bacteria specific binding compounds (2018-03-27),

11. 9822339 - Means and methods for influencing the stability of antibody producing cells (2017-11-21),

12. 9718876 - RSV G protein specific antibodies (2017-08-01),

13. 9718874 - Influenza A virus specific antibodies (2017-08-01),

14. 9688745 - Gram-positive bacteria specific binding compounds (2017-06-27),

15. 9458228 - Gram-positive bacteria specific binding compounds (2016-10-04),

AIMM Therapeutics B.V. is a biotechnology company specializing in the development of innovative antibody-based therapeutics. Committed to improving patient outcomes, AIMM Therapeutics focuses on the discovery and development of novel antibodies for the treatment of cancer and other diseases. With an experienced team of scientists and state-of-the-art facilities, AIMM Therapeutics aims to revolutionize the field of antibody therapeutics through cutting-edge research and clinical development.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

22 Patents

#1 in Amsterdam Zuidoost

#321 in Netherlands

#27,863 in the World

Amsterdam Zuidoost, Netherlands

Aimm Therapeutics B.v.

Forward Citations = 43

56 inventors:

Tim Beaumont (16 out of 29 patents)

Hergen Spits (13 out of 25 patents)

Mark Jeroen Kwakkenbos (12 out of 17 patents)

4. Eric J Brown (6 out of 12 patents)

5. Sanjeev Mariathasan (6 out of 16 patents)

Please report any incorrect information to support@idiyas.com

Loading…